Unicycive Therapeutics, Inc. UNCY

UNCY Company Overview

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney disease and related metabolic disorders. The company operates within the biopharmaceutical industry, with an emphasis on nephrology and chronic kidney disease (CKD) treatment markets. Its primary programs have centered on treatments intended to address complications associated with kidney failure and dialysis, including hyperphosphatemia in patients with CKD on dialysis. Public filings and investor materials identify the company’s lead product candidate as oxylanthanum carbonate (OLC), an investigational phosphate-binding agent designed to reduce pill burden compared with existing therapies.

The company’s business model is based on clinical development, regulatory advancement, and eventual commercialization or partnership-driven commercialization of its product candidates. Unicycive has positioned itself within a specialized segment of the nephrology market where treatment adherence and patient tolerability remain significant industry concerns. The company was founded in 2016 and became publicly traded on Nasdaq under the ticker UNCY following a reverse merger transaction. Since its formation, it has evolved from an early-stage therapeutic developer into a late clinical-stage company focused primarily on renal disease therapies.